http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
-
Regeneron (REGN) to Acquire Decibel Therapeutics (DBTX) for Over $4 Per Share
-
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs
-
Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation
-
Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS
-
Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023
-
Regeneron (REGN) Announces Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema
-
Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema
-
Regeneron (REGN) Announces FDA Issues CRL for Aflibercept 8 mg Biologics License Application Solely Due to Ongoing Review of Inspection Findings at Third-party Filler
-
FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
-
Regeneron's (REGN) Updated Linvoseltamab Data Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
-
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
-
Regeneron (REGN) Reports Fianlimab Combined with Libtayo Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
-
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
-
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
-
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
-
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
-
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
-
Regeneron Announces Investor Conference Presentations
-
Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation
-
Regeneron Reports First Quarter 2023 Financial and Operating Results
-
Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
-
Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
-
Regeneron (REGN) and Alnylam (ALNY) Report Positive Interim Phase 1 Clinical Data on ALN-APP
-
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
-
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
-
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
-
Regeneron (REGN) Announces Retirement of Board Chair
-
Regeneron (REGN) Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
-
Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
-
Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
-
Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases
-
Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases
-
Regeneron Announces Investor Conference Presentations
-
Regeneron Announces Investor Conference Presentations
-
Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023
-
Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023
-
Regeneron (REGN) Reports Libtayo in Combination with Chemotherapy Approved in EU as First-line Treatment of Advanced PD-L1 Positive NSCLC
-
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
-
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
-
Regeneron (REGN), Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
-
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
-
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
-
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
-
Sanofi (SNY) and Regeneron (REGN) Report Dupixent Met Endpoints in Phase 3 Trial for COPD
-
Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
-
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
-
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
-
Regeneron (REGN) Announces FDA Approval of Evkeeza
-
Regeneron (REGN) Announces FDA Approves First-in-class Evkeeza for Young Children with Ultra-rare Form of High Cholesterol